AI Terminal
DIACEUTICS PLC
Report Publication Announcement • May 29, 2024
7596_agm-r_2024-05-29_1fb33389-ec2c-4eca-8c1d-694b7e9f2afd.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1476Q
Diaceutics PLC
29 May 2024
Notice of AGM and Posting of Annual Report
Belfast and London, 29 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or the "Company"), a leading technology and solutions provider to the pharma and biotech industry announces that it has today posted its Annual Report for the year ended 31 December 2023 to shareholders together with the Notice of the 2024 Annual General Meeting ("AGM").
The Company will hold its AGM on Monday 24 June 2024 at 10.30 a.m at First Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park, Belfast, County Antrim BT9 6GW.
The Annual Report and Notice of AGM are now available on the Company's website at https://bit.ly/44VQLXK
Enquiries:
| Diaceutics PLC | |
| Nick Roberts, Chief Financial Officer Sally Craig, Company Secretary |
Tel: +44 (0)28 9040 6500 [email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde Kinvara Verdon Kieran Breheny |
[email protected] |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAMZGZKKRNGDZM